Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Meclofenamic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 13/20 | 0.97 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.75 |
| ▸ | MEN1 | O00255 | 2/20 | 0.97 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.97 |
| ▸ | GMNN | O75496 | 1/20 | 0.97 |
| ▸ | USP2 | O75604 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.97 |
| ▸ | GAA | P10253 | 1/20 | 0.97 |
| ▸ | MAPT | P10636 | 1/20 | 0.97 |
| ▸ | THRB | P10828 | 1/20 | 0.97 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.97 |
| ▸ | TSHR | P16473 | 1/20 | 0.97 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.97 |
| ▸ | BLM | P54132 | 1/20 | 0.97 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.97 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.97 |
| ▸ | METTL3 | Q86U44 | 2/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Meclofenamic Acid SCHEMBL29460464 | 1.00 | PTGS2 (0.97) | PTGS2MEN1MAPK1KMT2AGMNN | |
| Meclofenamic Acid SCHEMBL30384019 | 1.00 | PTGS2 (0.97) | PTGS2MEN1MAPK1KMT2AGMNN | |
| Meclofenamic Acid SCHEMBL4400214 | 0.99 | PTGS2 (1.00) | PTGS2MEN1MAPK1KMT2AGMNN | |
| Meclofenamic Acid SCHEMBL1874563 | 0.99 | PTGS2 (1.00) | PTGS2MEN1MAPK1KMT2AGMNN | |
| Meclofenamic Acid SCHEMBL3504 | 0.99 | PTGS2 (1.00) | PTGS2MEN1MAPK1KMT2AGMNN | |
| Meclofenamic Acid SCHEMBL30241166 | 0.99 | PTGS2 (1.00) | PTGS2MEN1MAPK1KMT2AGMNN | |
| Meclofenamic Acid SCHEMBL18171844 | 0.94 | PTGS2 (0.90) | PTGS2MEN1MAPK1KMT2AGMNN | |
| Meclofenamic Acid SCHEMBL1462647 | 0.88 | PTGS2 (0.79) | PTGS2MEN1MAPK1KMT2AGMNN | |
| Meclofenamic Acid SCHEMBL1538458 | 0.87 | PTGS2 (0.77) | PTGS2MEN1MAPK1KMT2AGMNN | |
| Meclofenamic Acid SCHEMBL8531474 | 0.87 | PTGS2 (0.77) | PTGS2MEN1MAPK1KMT2AGMNN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| EP-3575791-B1 | BLOOD TREATMENT METHOD AND BLOOD COLLECTION TUBE | ARKRAY INC (JP) | 2024-01-10 | — | — | EP | disclosed |
| CN-110547288-B | Blood processing method and blood collection tube | 爱科来株式会社 | 2022-09-02 | — | — | CN | disclosed |
| US-20210290676-A1 | IMPROVING THE EFFICACY AND SAFETY OF ADOPTIVE CELLULAR THERAPIES | ANGELES THERAPEUTICS, INC. | 2021-09-23 | — | — | US | disclosed |
| US-20200338114-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS RELATING TO INHIBITING FIBROUS ADHESIONS OR INFLAMMATORY DISEASE USING LOW SULPHATE FUCANS | ARC MEDICAL DEVICES INC. (CA) | 2020-10-29 | — | — | US | disclosed |
| CN-110547288-A | Blood processing method and blood collection tube | ARKRAY INC | 2019-12-10 | — | — | CN | disclosed |
| EP-3575791-A1 | BLOOD TREATMENT METHOD AND BLOOD COLLECTION TUBE | ARKRAY, Inc. (JP) | 2019-12-04 | — | — | EP | disclosed |
| US-20170252367-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS RELATING TO INHIBITING FIBROUS ADHESIONS OR INFLAMMATORY DISEASE USING LOW SULPHATE FUCANS | ARC MEDICAL DEVICES, INC. (CA) | 2017-09-07 | — | — | US | disclosed |
| US-20170246202-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS RELATING TO INHIBITING FIBROUS ADHESIONS OR INFLAMMATORY DISEASE USING LOW SULPHATE FUCANS | ARC MEDICAL DEVICES, INC. (CA) | 2017-08-31 | — | — | US | disclosed |
| US-20140256672-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS RELATING TO INHIBITING FIBROUS ADHESIONS OR INFLAMMATORY DISEASE USING LOW SULPHATE FUCANS | ARC MEDICAL DEVICES, INC. (CA) | 2014-09-11 | — | — | US | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| EP-1809303-A4 | PHARMACEUTICAL COMPOSITIONS AND METHODS RELATING TO INHIBITING FIBROUS ADHESIONS OR INFLAMMATORY DISEASE USING LOW SULPHATE FUCANS | ARC PHARMACEUTICALS INC (CA) | 2008-12-24 | — | — | EP | disclosed |
| US-20080063682-A1 | Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans | ARC MEDICAL DEVICES, INC. (CA) | 2008-03-13 | — | — | US | disclosed |
| EP-1809303-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS RELATING TO INHIBITING FIBROUS ADHESIONS OR INFLAMMATORY DISEASE USING LOW SULPHATE FUCANS | ARC PHARMACEUTICALS, INC. (CA) | 2007-07-25 | — | — | EP | disclosed |
| CN-1829501-A | Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents | ARC PHARMACEUTICALS INC (CA) | 2006-09-06 | — | — | CN | disclosed |
| WO-2006032143-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS RELATING TO INHIBITING FIBROUS ADHESIONS OR INFLAMMATORY DISEASE USING LOW SULPHATE FUCANS | ARC PHARMACEUTICALS, INC. (CA) | 2006-03-30 | — | — | WO | disclosed |
| WO-2006032144-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS RELATING TO INHIBITING FIBROUS ADHESIONS OR INFLAMMATORY DISEASE USING FUCANS FROM VARIOUS ECHINODERM SOURCES | ARC PHARMACEUTICALS, INC. (CA) | 2006-03-30 | — | — | WO | disclosed |
| EP-1631265-A2 | USE OF VARIOUS AGENTS FOR INHIBITING FIBROUS ADHESIONS | ARC PHARMACEUTICALS, INC. (CA) | 2006-03-08 | — | — | EP | disclosed |
| WO-2004105737-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS RELATING TO INHIBITING FIBROUS ADHESIONS USING VARIOUS AGENTS | ARC PHARMACEUTICALS, INC. (CA) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | PTGS2 24/4885PTGS1 263/4885MEN1 4053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.